Giving guarantees/indemnity/ becoming a surety for third party

Ref: NEPHROPLUS/SE/55 June 25, 2026 To To BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, 5th Floor, Exchange Plaza, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 544647 Scrip Symbol: NEPHROPLUS Through: BSE Listing Centre Through: NEAPS Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby inform the following: a. This has reference to the outcome of the Board Meeting submitted on January 15, 2026 vide letter no. NEPHROPLUS/SE/2025-26/10, wherein the Company had informed the Stock Exchanges regarding the approval granted by the Board of Directors for issuance of a Corporate Guarantee in favour of Citibank N.A., and/or any other overseas lender, on behalf of Nephrocare Health Care Services Philippines Inc., Philippines ("NHCSPI"), an overseas step-down wholly-owned subsidiary of the Company, for an aggregate amount not exceeding USD 6.00 million. Pursuant to the aforesaid approval, the Company has executed a Corporate Guarantee Agreement dated May 29, 2026 in favour of Citibank N.A. for securing the credit facilities availed by NHCSPI. The Corporate Guarantee has been issued for an amount of USD 5,500,000 (equivalent to INR 52.46 Crore). The Company had duly disclosed the Board approval for issuance of the aforesaid Corporate Guarantee on January 15, 2026. However, the execution of the Corporate Guarantee Agreement was not separately intimated at the relevant time due to an inadvertent administrative reason. The Company is accordingly making this disclosure and shall ensure timely reporting of similar events going forward. b. Further, this has reference to our letter bearing reference no. NEPHROPLUS/SE/34 dated May 19, 2026, whereby the Company had informed the Stock Exchanges regarding the approval granted by the Board of Directors for providing collateral/security support in favour of The Hongkong and Shanghai Banking Corporation Limited ("HSBC") and/or its affiliates, branches or designated lending offices, for the benefit of Nephrocare Health Services International Pte. Ltd. ("NHSI"), Singapore, an overseas wholly-owned subsidiary of the Company. In this regard, we hereby inform you that the Company has provided collateral/security support on June 24, 2026, which is effective from June 18, 2026, in favour of HSBC for the benefit of NHSI, Singapore, to enable NHSI to avail fund-based and/or non-fund-based credit facilities. The aggregate financial commitment undertaken by the Company pursuant to the aforesaid transaction amounts to USD 3,315,622 (equivalent to INR 31.26 Crore). The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as Annexure I. The aforesaid information is also being made available on the Company's website at www.nephroplus.com For Nephrocare Health Services Limited (Formerly Nephrocare Health Services Private Limited) Kishore Kathri Company Secretary & Compliance Officer ICSI M.No. F9895 Encl: a/a ANNEXURE I Sr. Particulars Description 1. Name of party for which such Nephrocare Health Care Nephrocare Health Services guarantees or indemnity or Services Philippines Inc. International Pte. Ltd. (NHSI), surety was given (NHCSPI), Philippines, an Singapore, an overseas wholly- overseas step down wholly- owned subsidiary of the owned subsidiary of the Company. Company. 2. Whether the promoter/ The transaction has been undertaken for the benefit of the said promoter group/ group overseas entities. The promoter(s), promoter group and group companies have any interest companies do not have any direct or indirect interest in the in this transaction? If yes, transaction, other than to the extent of their shareholding nature of interest and details interest in the Company. The transaction has been undertaken thereof and whether the same in the ordinary course of business and on an arm's length basis. is done at “arm’s length”; 3. Brief details of such guarantee The Company has executed a The Company has provided or indemnity or becoming a Corporate Guarantee collateral/security support on surety viz. brief details of Agreement dated May 29, June 24, 2026, which is agreement entered (if any) 2026 in favour of Citibank effective from June 18, 2026 in including significant terms and N.A. on behalf of Nephrocare favour of The Hongkong and conditions, including amount Health Care Services Shanghai Banking Corporation of guarantee; Philippines Inc. (NHCSPI), Limited ("HSBC") and/or its Philippines, an overseas step affiliates, branches or down wholly-owned designated lending offices, for subsidiary of the Company, the benefit of Nephrocare for securing credit facilities Health Services International availed/to be avialed by Pte. Ltd. (NHSI), Singapore, an NHCSPI. The aggregate overseas wholly-owned amount of the Corporate subsidiary of the Company. Guarantee is USD 5,500,000 (equivalent to INR 52.46 The aggregate financial Crore). commitment undertaken by the Company is USD 3,315,622 The Corporate Guarantee (equivalent to INR 31.26 shall remain valid in Crore). accordance with the terms of the Corporate Guarantee Agreement and the underlying credit facility documents. 4. Impact of such guarantees or The Corporate Guarantee The transaction results in a indemnity or surety on listed creates a contingent financial financial commitment by the entity obligation on the Company to Company of USD 3,694,321 the extent of USD 5,500,000 (equivalent to INR 31.26 (equivalent to INR 52.46 Crore) by way of providing Crore). The guarantee has collateral/security support in been issued on behalf of favour of HSBC for the benefit Nephrocare Health Care of Nephrocare Health Services Services Philippines Inc., International Pte. Ltd., Philippines, an overseas step- Singapore, an overseas wholly- down wholly-owned owned subsidiary of the subsidiary of the Company, to Company. The transaction support its financing creates a contingent financial requirements and business exposure on the Company to operations. the extent of the aforesaid amount. Other than the aforesaid contingent financial Other than the aforesaid obligation, no immediate contingent financial exposure, impact on the operations, no immediate impact on the liquidity or cash flows of the operations, liquidity or cash Company is envisaged. flows of the Company is envisaged.